ISTA’s Bromday Hearing Request Should Be Deferred Pending Cmte. Review, CDER Says
This article was originally published in The Pink Sheet Daily
Center for Drug Evaluation and Research tells FDA Commissioner Margaret Hamburg that resource and regulatory policy considerations warrant postponing action on ISTA’s request for a formal evidentiary hearing on its rejected application for a larger fill size.
You may also be interested in...
FDA urged consideration of additional pre-market safety studies for the vitreomacular adhesion product, but desire for an additional treatment option for a condition that at present is treated only with surgery overrode potential concerns about visual acuity side effects.
Specter of Bromday Dispute Will Haunt Advisory Panel Discussion of Ophthalmic Product Labeling Changes
Ista Pharmaceuticals’ rejected sNDA for a larger fill size of its ocular agent Bromday won’t be on the formal agenda, but the company will be presenting at the meeting, and the subject is bound to be on the minds of FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee.
The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.